Department of Clinical Microbiology and Immunology, Sir Ganga Ram Hospital, Rajinder Nagar, New Delhi 110060, India.
Indian J Pediatr. 2013 Jan;80(1):70-1. doi: 10.1007/s12098-011-0669-5. Epub 2011 Dec 29.
Shigellosis is endemic in many resource-poor countries due to feco-oral transmission, resulting in considerable morbidity and mortality. There is rapid emergence of multi-drug resistant (MDR) Shigella spp. resulting in poor reliability of first line antibiotics like quinolones, co-trimoxazole and ampicillin. Ceftriaxone has been used as a reserved antibiotic for treatment of MDR Shigella spp. The authors report a case of ceftriaxone resistant Shigella flexneri successfully managed with meropenem. As occurrence of ceftriaxone resistant Shigella is still rare, the objective of reporting this case is to highlight the possible failure of ceftriaxone in treating shigellosis which if not detected timely can result in mortality.
志贺菌病由于粪-口传播在许多资源匮乏的国家流行，导致发病率和死亡率相当高。由于耐多药（MDR）志贺菌属的迅速出现，导致喹诺酮类、复方磺胺甲噁唑和氨苄西林等一线抗生素的可靠性降低。头孢曲松已被用作治疗 MDR 志贺菌属的保留抗生素。作者报告了一例成功用美罗培南治疗的头孢曲松耐药福氏志贺菌。由于头孢曲松耐药志贺菌的发生仍然很少见，报告此病例的目的是强调头孢曲松治疗志贺菌病可能失败，如果不及时发现，可能导致死亡。
